ORLANDO, Fla. (AP) -- Biotech drug developer Antigenics Inc. said Thursday its cancer vaccine Oncophage produced a specific immune response to cancer of the nervous system.
In a early-to-midstage clinical trial, six patients with high-grade glioma given Oncophage showed an immune reponse specific to their tumors. Glioma is a cancer that affects the connective tissue cells that surround and support nerve cells.
"This is the first documentation of a glioma-specific immune response after vaccination with Oncophage," said Dr. Andrew T. Parsa, a principal investigator in the trial.
Oncophage uses material from an individual's tumor to reprogram the body's immune system to attack target cells with similar genetic material.
Antigenics shares rose 6 cents, or 2.6 percent, to $2.37 in afternoon trading on the Nasdaq.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment